Skip To Main Content
Lilly
Menu closed
Lilly

    COVID-19 Journal Publications

    This page includes links to Lilly sponsored clinical trials that have been published in peer reviewed journals over the last 3 years. Each section is sorted by product and may be expanded by each phase. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.

    If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please Contact Lilly services.

    bamlanivimab

    Healthcare providers should direct questions about bamlanivimab alone or about the revocation of Emergency Use Authorization (EUA) 90, Eli Lilly and Company
    at 1-855-LillyC19 (1-855-545-5921)

    Bamlanivimab has not been approved, but has been authorized for emergency use by FDA, to treat mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization*.* Bamlanivimab is an investigational drug that has not been approved by the FDA for any use. It is not yet known if bamlanivimab is safe and effective for the treatment of COVID-19. This use is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use, unless the authorization is terminated or revoked sooner.

    SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
    Published Date: October 28, 2020

    bamlanivimab and etesevimab together

    HCP Fact Sheet | Patient & Caregiver Fact Sheet | FDA Authorization Letter

    Bamlanivimab and etesevimab together is authorized for use under an Emergency Use Authorization for the treatment of mild to moderate COVID-19 illness in adults and pediatric patients 12 years and older, who weigh at least 40 kg, who are at high risk for progressing to severe COVID-19 illness and/or hospitalization. Bamlanivimab and etesevimab together is an investigational drug that has not been approved by the FDA for any use. It is not yet known if bamlanivimab and etesevimab together is safe and effective for the treatment of COVID-19. This use is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use, unless the authorization is terminated or revoked sooner.

    Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial
    Published Date: January 21, 2021

    Can't find what you're looking for? Contact us for answers to your medical questions.

    • Copyright
    • Terms of Use
    • Privacy Statement
    • Accessibility Statement
    • Sitemap
       

      This site is intended for US Healthcare Professionals only.

      4.0.2 03/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

      Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

      Facebook Twitter LinkedIn
      Lilly